X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cobicistat (241) 241
humans (239) 239
index medicus (207) 207
hiv infections - drug therapy (194) 194
infectious diseases (135) 135
emtricitabine (125) 125
pharmacology & pharmacy (122) 122
male (119) 119
hiv (117) 117
double-blind (115) 115
tenofovir (107) 107
female (104) 104
adult (99) 99
initial treatment (95) 95
elvitegravir (93) 93
anti-hiv agents - therapeutic use (90) 90
middle aged (84) 84
adenine - analogs & derivatives (82) 82
anti-hiv agents - administration & dosage (81) 81
immunology (79) 79
drug combinations (78) 78
co-formulated elvitegravir (70) 70
pharmacokinetics (70) 70
antiretroviral therapy (65) 65
hiv infection (63) 63
ritonavir (63) 63
anti-hiv agents - adverse effects (61) 61
human immunodeficiency virus--hiv (61) 61
hiv-1 - drug effects (56) 56
treatment outcome (55) 55
drug interactions (54) 54
disoproxil fumarate (51) 51
tenofovir disoproxil fumarate (51) 51
antiviral agents (49) 49
quinolones - therapeutic use (48) 48
darunavir (47) 47
drug therapy, combination (47) 47
quinolones - administration & dosage (47) 47
drug therapy (46) 46
hiv infections - virology (45) 45
cobicistat - administration & dosage (44) 44
adenine - administration & dosage (43) 43
antiretroviral drugs (43) 43
microbiology (43) 43
aids/hiv (42) 42
adenine - therapeutic use (41) 41
virology (41) 41
cobicistat - therapeutic use (40) 40
tenofovir alafenamide (39) 39
safety (37) 37
open-label (36) 36
raltegravir (36) 36
dosage and administration (35) 35
infection (35) 35
dolutegravir (34) 34
hiv-1 (34) 34
protease inhibitors (34) 34
carbamates - administration & dosage (33) 33
thiazoles - administration & dosage (33) 33
deoxycytidine - analogs & derivatives (32) 32
anti-hiv agents - pharmacokinetics (30) 30
thiazoles - therapeutic use (30) 30
carbamates - therapeutic use (29) 29
hiv-1 infection (29) 29
quinolones - adverse effects (29) 29
ritonavir - therapeutic use (29) 29
efavirenz (28) 28
efficacy (28) 28
non-inferiority trial (28) 28
phase-3 (28) 28
adenine - adverse effects (27) 27
cobicistat - adverse effects (27) 27
emtricitabine - therapeutic use (27) 27
tenofovir - therapeutic use (27) 27
therapy (27) 27
viral load (27) 27
anti-hiv agents - pharmacology (26) 26
pharmacoenhancer (26) 26
pharmacology (26) 26
young adult (26) 26
atazanavir (25) 25
health aspects (25) 25
highly active antiretroviral therapy (25) 25
organophosphonates - administration & dosage (24) 24
organophosphonates - therapeutic use (24) 24
cobicistat - pharmacokinetics (23) 23
deoxycytidine - administration & dosage (23) 23
deoxycytidine - therapeutic use (23) 23
drug resistance, viral (23) 23
treatment-naive (23) 23
analysis (22) 22
emtricitabine - administration & dosage (22) 22
fixed-dose combination (22) 22
hiv protease inhibitors - therapeutic use (22) 22
research (22) 22
ritonavir - administration & dosage (22) 22
virus diseases (22) 22
adults (21) 21
aged (21) 21
antiretroviral agents (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 9, pp. 1876 - 1893
Abstract Purpose This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug... 
Internal Medicine | Medical Education | HIV | cobicistat | pharmacokinetic enhancer | booster | GS-9350 | PLUS EMTRICITABINE/TENOFOVIR DF | COFORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | OPEN-LABEL | MECHANISM-BASED INACTIVATION | CYTOCHROME-P450 ENZYMES | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Anti-HIV Agents - pharmacology | Darunavir - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | HIV-1 - drug effects | Humans | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Cobicistat - pharmacokinetics | Drug Interactions | Quinolones - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Quinolones - therapeutic use | Anti-HIV Agents - therapeutic use | Cobicistat - pharmacology | HIV Infections - drug therapy | Cobicistat - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Drug Therapy, Combination | Darunavir - therapeutic use | HIV Infections - metabolism | Drugstores | HIV (Viruses) | Health aspects | HIV infection | Pharmacy | Cytochrome | Antiretroviral drugs | Enzymes | Mortality | Clinical trials | Pharmacology | Infections | Metabolism | Molecular weight | Human immunodeficiency virus--HIV | Trademarks | Adults | Pharmaceutical industry | Drug dosages
Journal Article
Journal Article
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 461
Background: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons. Objective:... 
INDIVIDUALS | TRIAL | MEDICINE, GENERAL & INTERNAL | THERAPY | COBICISTAT | DISOPROXIL FUMARATE | RISK | RITONAVIR
Journal Article
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir... 
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | CHEMISTRY, ANALYTICAL | LABELED INTERNAL STANDARDS | ELVITEGRAVIR | EMTRICITABINE | IMPLEMENTATION | HUMAN-IMMUNODEFICIENCY-VIRUS | TANDEM MASS-SPECTROMETRY | REVERSE-TRANSCRIPTASE INHIBITOR | PHARMACOKINETICS | PRODRUG | PHARMACOLOGY & PHARMACY | SIMULTANEOUS QUANTIFICATION | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 3635 - 3643
A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine [FTC]), and tenofovir... 
Darunavir/cobicistat | protease inhibitors | Inhibitors | HIV | Emtricitabine/tenofovir alafenamide | CHEMISTRY, MEDICINAL | BONE-MINERAL DENSITY | BOOSTED DARUNAVIR | OPEN-LABEL | HUMAN-IMMUNODEFICIENCY-VIRUS | GLOMERULAR-FILTRATION-RATE | darunavir/cobicistat | emtricitabine/tenofovir alafenamide | DISOPROXIL FUMARATE | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | FIXED-DOSE COMBINATION | HEALTHY-VOLUNTEERS | ANTIRETROVIRAL-NAIVE ADULTS | Anti-HIV Agents - pharmacology | Adenine - analogs & derivatives | Humans | Cobicistat - administration & dosage | Adenine - pharmacology | Emtricitabine - pharmacology | HIV - drug effects | Adenine - administration & dosage | Randomized Controlled Trials as Topic | Anti-HIV Agents - administration & dosage | Protease Inhibitors - pharmacology | Darunavir - pharmacology | Darunavir - administration & dosage | Protease Inhibitors - administration & dosage | Cobicistat - pharmacology | HIV Infections - drug therapy | Drug Combinations | Emtricitabine - administration & dosage | Drugs | Medical research | Antiviral agents | Atazanavir | Darunavir | AIDS treatment | Isoenzymes | Cytochrome P-450 | Anti-HIV agents | Infection | Rifabutin | Proteases | Analysis | Medicine, Experimental | Reverse transcriptase inhibitors | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Ritonavir | Central nervous system | Clinical trials | Nervous system | Infections | Density | Tenofovir | Beryl | Protease | Human immunodeficiency virus--HIV | Safety | Creatinine | Emtricitabine | Antiretroviral drugs | Kidneys | Effectiveness | Health risks | Pharmacology | Proteinase inhibitors | Patients | Cholesterol | Protease inhibitors | Bone | Pharmacokinetics | Cardiovascular diseases | Cytochrome | Cardiovascular disease | Bone density | Drug dosages | Urine | Enzymes
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 05/2015, Volume 4, Issue 3, pp. 218 - 225
This randomized, two‐way crossover study evaluated the bioavailability of elvitegravir administered as the new individual tablet containing 150 mg and a... 
HIV integrase strand transfer inhibitor | Japanese | elvitegravir | bioequivalence | stribild | Elvitegravir | Bioequivalence | Stribild | INTEGRASE | EMTRICITABINE | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | TOXIN EXTRUSION 1 | HUMAN MULTIDRUG | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | HIV-1 INFECTION | TENOFOVIR | Tablets | Area Under Curve | Humans | Middle Aged | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Male | Metabolic Clearance Rate | Healthy Volunteers | Anti-HIV Agents - administration & dosage | Young Adult | Quinolones - adverse effects | Quinolones - pharmacokinetics | Adult | Drug Therapy, Combination | Drug Administration Schedule | Administration, Oral | Anti-HIV Agents - adverse effects | Japan | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Cobicistat - administration & dosage | Cross-Over Studies | Quinolones - administration & dosage | Cobicistat - pharmacokinetics | Models, Biological | Anti-HIV Agents - pharmacokinetics | Least-Squares Analysis | Cobicistat - adverse effects | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacokinetics | Therapeutic Equivalency
Journal Article
Journal Article
Infection, ISSN 0300-8126, 2/2019, Volume 47, Issue 1, pp. 115 - 119
Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF).We present the first report of suicidal attempt... 
Medicine & Public Health | General Practice / Family Medicine | Infectious Diseases | Internal Medicine | Overdose | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Suicide attempt | INFECTIOUS DISEASES | ELVITEGRAVIR | COBICISTAT | EMTRICITABINE | OPEN-LABEL | DOLUTEGRAVIR | COMBINATION | TENOFOVIR DISOPROXIL FUMARATE | PHARMACOKINETICS | SINGLE-TABLET REGIMEN | HIV-1 INFECTION | Emtricitabine - adverse effects | Adenine - analogs & derivatives | Drug Overdose - diagnosis | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Cobicistat - administration & dosage | Male | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Quinolones - administration & dosage | Adenine - adverse effects | Quinolones - adverse effects | Renal Insufficiency - chemically induced | Renal Insufficiency - physiopathology | Suicide, Attempted | Cobicistat - adverse effects | HIV Infections - drug therapy | Drug Overdose - complications | Drug Combinations | Emtricitabine - administration & dosage | Complications and side effects | Antiviral agents | Suicidal behavior | Dosage and administration | Research | Drug therapy | HIV infection | Risk factors | Anti-HIV agents | Integrase | Emtricitabine | Tenofovir | Kidneys | Human immunodeficiency virus--HIV | Renal failure | Suicides & suicide attempts | Viruses | Suicide
Journal Article
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 11/2016, Volume 16, Issue 1, p. 718
Journal Article